16.3%) compared with those in Western reports, possibly reflecting that ERG expression vary according to racial backgrounds. 10 In this study, ERG expression was associated with a less aggressive tumor phenotype such as lower Gleason score and negative surgical margin. Reports on the frequencies of ERG alterations among races have been consistent, with men of European ancestry having the highest rates of alteration and men of African and Asian ancestries having considerably lower alteration rates. 11 On the other hand, the reported prognostic association of ERG rearrangement, ERG protein expression, or transcript detection have been conflicting. 11 Many reports indicated that ERG expression was associated with more aggressive disease, 4, 12, 13 although some documented no 14 or negative association. 10, 15, 16 Variations in assay platforms, specimen types, and self-reported ethnicity may be possible bias influencing on the inconsistent results.
11
Overexpression of serine protease inhibitor Kazal-type 1 (SPINK1) has been identified in approximately 5.9-15.3% cases of localized PCa. 17, 18 In most studies, SPINK1 was almost exclusively defined in ERG-negative PCa. Although the association of SPINK1 overexpression with an aggressive PCa phenotype has been reported, some studies reported conflicting results, and the roles of SPINK1 and ERG remain controversial. [19] [20] [21] [22] PCa accidentally found during cystoprostatectomy for bladder cancer is called incidental cancer. 
| Statistical analysis
Statistical analyses were conducted to determine the association between ERG and SPINK1 expression and patient age, PSA, specimen
Gleason score, and metastatic status. Kaplan-Meier projection and the log-rank test were conducted to compare time to CRPC and overall survival between groups. Significance was set at <5%. All statistical analyses were conducted using a commercially available software package (Prism 5.0, GraphPad Software, Inc., San Diego, CA).
3 | RESULTS
| Patient demographics
The prevalence of incidental cancer stratified by age groups is shown in Table 1 . The overall prevalence was 32.2% (46/143) ( Table 1 ). Eighteen of the 46 patients with incidental cancer had multiple foci in the prostate: 12 patients had two foci, five had three and one had four. 
| Immunohistochemical analysis of ERG and SPINK1
Representative findings of ERG and SPINK1 immunohistochemical analyses are shown in Figure 1 . ERG protein expression was observed in malignant cells, endothelial cells, and lymphocytes, consistent with a previous report. 10 Majority of the ERG-positive tumors showed more than 95% cell positivity and uniform intensity ( Figures 1A and 1B 
| Clinicopathological characteristics classified by ERG and SPINK1 status in metastatic cohort
Consistent with other reports, SPINK1 was almost exclusively found in ERG-negative PCa, and only one tumor in the metastatic cohort expressed both SPINK1 and ERG. Except for the patient expressing both ERG and SPINK1, the metastatic cohort was further classified to ERG + (n = 13), SPINK1 + (n = 11), and ERG − / SPINK1 − (n = 73) subgroups. The clinicopathological characteristics of the patients classified according to ERG and SPINK1 status are shown in Table 4 .
ERG and SPINK1 expression status was not significantly associated with the pre-treatment characteristics (ie, age, PSA, Gleason score, and metastatic status). Meanwhile, SPINK1 expression was significantly associated with a shorter time to CRPC (P = 0.048, Figure 2A ). By contrast, overall survival was not significantly associated with the expression status of ERG and SPINK1 (P = 0.71, Figure 2B ). On the other hand, SPINK1 expression was reported to be relatively low in PCa regardless of race. 22 In this study, SPINK1
expression was observed in 6.5% and 12.2% of specimens in the incidental and metastatic cohorts, respectively, and this result was consistent with those of previous reports. Conflicting results about SPINK1 expression and prognosis of PCa have been reported in patients with organ-confined disease. 22 The frequencies of SPINK1 expression in the incidental and metastatic cohorts in this study were not statistically different. This study has several limitations. First, the number of patients was relatively small. Second, some of the patients in the incidental PCa cohort lacked PSA data. Third, the period of sample collection in the metastatic cohort was relatively old and most of patients were not administrated with new drugs such as abiraterone acetate, enzalutamide, and cabazitaxel. OS in this cohort might not reflect those in the recent CRPC patients. Finally, the type of specimens was different in the current study from those mentioned previously. The difference might influence the frequencies of ERG and SPINK1 expression between the cohorts.
| CONCLUSIONS
The frequencies of both ERG and SPINK1 expression were not significantly different between the incidental and metastatic PCa, suggesting that ERG expression may not have a significant influence on the metastatic behavior of PCa. SPINK1 expression was significantly associated with a shorter time to CRPC in the metastatic PCa cohort.
The expression profile of ERG and SPINK1 may be a useful predictor for effect of androgen deprivation therapy in patients with metastatic castration-sensitive PCa.
